Observational studyBMC infectious diseases2026
Interferon-gamma autoantibodies in patients with infectious uveitis: a pilot case-control study.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the association between infectious uveitis in immunocompetent individuals and adult-onset immunodeficiency (AOID).
methodsA pilot prospective observational case-control study was conducted involving 28 patients with infectious uveitis unrelated to human immunodeficiency virus (non–HIV). These patients were categorized into two groups: Cytomegalovirus (CMV)–associated uveitis (n = 15) and non–CMV infectious uveitis (n = 13). Blood donors (n = 41) served as controls to establish the positivity threshold for interferon-gamma (IFN-γ) autoantibodies. Autoantibody and neutralizing autoantibody levels were measured using indirect and competitive ELISA methods, respectively. Demographic data, key clinical characteristics, disease course and laboratory investigations—including complete blood count, anti–HIV antibody test, and CD4+ T-cell count—were collected from participants.
resultsOne patient in the CMV group tested positive for IFN-γ autoantibodies (level: 1.02), exceeding the 99th percentile positivity threshold defined by the control group. This patient, diagnosed with AOID, also had the highest neutralizing autoantibodies level (41.02%) and presented with severe CMV anterior uveitis and endotheliitis leading to bullous keratopathy and corneal decompensation. There were no differences in demographic data or basic immunologic parameters between the CMV and non-CMV groups. Likewise, no significant differences in IFN-γ autoantibody level were observed among cases and controls, with median (IQR) value of 0.15 (0.12–0.21) in CMV group; 0.14 (0.11–0.17) in non-CMV groups; and 0.14 (0.12–0.18) in control group (P > .05).
conclusionsIn this pilot study, one patient with severe CMV–associated uveitis was identified as having underlying AOID. The findings are hypothesis-generating, and an association cannot be established from the current data. The pathogenesis of infectious uveitis in presumed immunocompetent individuals remains unclear and warrants further investigation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.